Business Standard

Lupin launches combination drug for patients with heart failure conditions

The company said it has introduced Sacubitril and Valsartan under two brand names, Valentas and Arnipin, in strengths of 200 mg, 100 mg, and 50 mg, in India

Lupin, Boehringer Ingelheim ink $700-mn deal for anti-cancer drug

Valentas and Arnipin are indicated to reduce repeated hospitalisation and the risk of cardiovascular death among adult patients with chronic mild to moderate heart failure

Press Trust of India New Delhi
Drug maker Lupin on Wednesday said it has launched a combination drug for patients with heart failure (HF) conditions.
The company said it has introduced Sacubitril and Valsartan under two brand names, Valentas and Arnipin, in strengths of 200 mg, 100 mg, and 50 mg, in India.
In India, HF remains one of the most prevalent causes of death in patients suffering from chronic heart failure and the estimated prevalence ranges from 1.3 to 4.6 million, the drug maker said in a statement.
Valentas and Arnipin are indicated to reduce repeated hospitalisation and the risk of cardiovascular death among adult patients with chronic mild to moderate heart failure.
"The launch of Valentas and Arnipin aligns with this commitment and offers patients an important treatment option and fulfils an unmet need, while reducing the cost of therapy," Lupin President - India Region Formulations Rajeev Sibal stated.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Jan 18 2023 | 7:14 PM IST

Explore News